Dechra Pharmaceuticals PLC — Director's Dealing 2017

Mar 21, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1005A

Dechra Pharmaceuticals PLC

21 March 2017

21 March 2017

Dechra Pharmaceuticals PLC

(the Company)

Director Shareholding

Dechra Pharmaceuticals PLC has been notified that on 21 March 2017 Anthony Griffin, Executive Director, sold 3,500 ordinary shares in the Company at a price of £16.76 each. 

Following this acquisition, Anthony Griffin's beneficial interest in the Company is 64,320 shares (0.069% of the current issued share capital).

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

Notification of Dealing Form

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Anthony Griffin
2.	Reason for the notification
a)	Position/status	Director
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Dechra Pharmaceuticals PLC
b)	LEI code	N/A
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 1 pence each ISIN: GB0009633180
b)	Nature of the transaction	Sale of Shares
c)	Price(s) and volumes(s)	Price(s) 16.76	Volume(s) 3,500
d)	Aggregated information -   Aggregate volume -   Price -   Total	3,500 £16.76 £58,660.00
e)	Date of the transaction	2017.03.21
f)	Place of the transaction	London Stock Exchange

For further information, please contact:

Suzana Cross, Company Secretary           

Telephone number: 01606 814730

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHOKDDKQBKDFNB